Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 40

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 40
---
 entered into voting and support agreements with Kaken and Aadi (the “Support Agreements”) with respect to [●] shares of common stock as of the Record Date, representing [●]% of shares
outstanding. The Support Agreements obligate the directors and executive officers of Aadi (including certain of their affiliated entities) to vote their respective shares of our common stock in favor of the approval of the Divestiture Agreement and
the Divestiture and certain related matters, and against certain matters that would reasonably be expected to impede, interfere with, delay, discourage, adversely affect or inhibit the transactions contemplated by the Divestiture Agreement. In
(1) evaluating and negotiating the Divestiture Agreement; (2) approving the Divestiture Agreement and the transactions contemplated by the Divestiture Agreement, including the Divestiture; and (3) recommending that Aadi stockholders
vote in favor of the approval of the Divestiture Agreement and the Divestiture, Aadi’s board of directors was aware of and considered these interests to the extent that they existed or were otherwise known at the time, among other matters.

Retention Bonus Letters

We have entered into retention
bonus letters (each, a “Retention Bonus Letter”) with each of Dr. Lennon and Messrs. Giacobello and Ball, pursuant to which the executives are eligible to be paid retention bonuses (each, a “Retention Bonus”) subject to
continued employment with us through the earlier of (i) March 31, 2025, or (ii) the date of a Change in Control (as defined in the applicable Retention Bonus Letter), provided that an executive will remain eligible to receive the
Retention Bonus if his employment is terminated by us other than for Cause, death or disability, or if he resigns for Good Reason (each such term as defined in the applicable Retention Bonus Letter), subject to execution of a separation agreement
and release of claims in favor of Aadi. Although it is expected that the Divestiture will notconstitute a Change in Control for purposes of the Retention Bonus Letters, in an abundance of caution, we are treating the Retention Bonus
Letter as an interest of the Executive Officers in the Divestiture for purposes of this proxy statement. The amount of such Retention Bonus is $390,000 for Dr. Lennon, $220,000 for Mr. Giacobello and $210,000 for Mr. Ball.

Additionally, it is expected that Dr. Lennon, Mr.